Valuation : Avacta Group Plc

Market Cap 342M 463M 399M 377M 642M 44.18B 645M 4.49B 1.72B 22.46B 1.74B 1.7B 71.04B P/E 2026 *
-11.3x
P/E 2027 * -13.2x
Enterprise Value 339M 458M 395M 374M 635M 43.74B 639M 4.44B 1.71B 22.24B 1.72B 1.68B 70.35B EV / Sales 2026 *
123x
EV / Sales 2027 * 44.5x
Free-Float
97.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Avacta Group Plc

Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 60 03/02/2020
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Change 5-day change 1-year change 3-year change Capi.($)
-2.11%-3.44%+41.04%+98.48% 68.24B
-0.23%-6.42%+30.19%+76.15% 62.23B
+1.67%+2.16%-11.32%+392.80% 27.8B
-1.05%-7.30%+25.00%+12.31% 24.86B
+0.34%-5.98%-4.23%-19.48% 24.22B
+0.43%-4.78%+18.26%-20.61% 19.36B
-3.03%-5.19%+192.88%+340.13% 17.28B
-1.94%-6.36%-7.05%+516.16% 14.46B
-2.28%-5.09%+48.86%+153.82% 14.23B
Average -0.91%-3.96%+37.07%+172.20% 30.3B
Weighted average by Cap. -0.86%-3.80%+33.61%+136.95%

Financials

2026 *2027 *
Net sales 2.74M 3.71M 3.2M 3.03M 5.15M 354M 5.18M 35.99M 13.82M 180M 13.92M 13.63M 570M 8.12M 10.98M 9.46M 8.96M 15.23M 1.05B 15.32M 106M 40.88M 533M 41.2M 40.33M 1.69B
Net income -28.92M -39.11M -33.71M -31.9M -54.26M -3.74B -54.56M -379M -146M -1.9B -147M -144M -6.01B -23.64M -31.97M -27.56M -26.08M -44.35M -3.05B -44.6M -310M -119M -1.55B -120M -117M -4.91B
Net Debt -3.33M -4.51M -3.89M -3.68M -6.26M -431M -6.29M -43.75M -16.79M -219M -16.92M -16.57M -693M 18.99M 25.69M 22.14M 20.95M 35.64M 2.45B 35.84M 249M 95.65M 1.25B 96.39M 94.35M 3.95B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!